» Articles » PMID: 38164628

Advances in the Management of Pancreatic Cancer

Overview
Journal BMJ
Specialty General Medicine
Date 2024 Jan 2
PMID 38164628
Authors
Affiliations
Soon will be listed here.
Abstract

Pancreatic cancer remains among the malignancies with the worst outcomes. Survival has been improving, but at a slower rate than other cancers. Multimodal treatment, including chemotherapy, surgical resection, and radiotherapy, has been under investigation for many years. Because of the anatomical characteristics of the pancreas, more emphasis on treatment selection has been placed on local extension into major vessels. Recently, the development of more effective treatment regimens has opened up new treatment strategies, but urgent research questions have also become apparent. This review outlines the current management of pancreatic cancer, and the recent advances in its treatment. The review discusses future treatment pathways aimed at integrating novel findings of translational and clinical research.

Citing Articles

The global, regional burden of pancreatic cancer and its attributable risk factors from 1990 to 2021.

Yu W, Zhou D, Meng F, Wang J, Wang B, Qiang J BMC Cancer. 2025; 25(1):186.

PMID: 39891086 PMC: 11786447. DOI: 10.1186/s12885-025-13471-y.


Genetically predicted causal link between the plasma lipidome and pancreatic diseases: a bidirectional Mendelian randomization study.

Lin L, Huang Y, Qian S, Chen L, Sun H Front Nutr. 2025; 11:1466509.

PMID: 39882037 PMC: 11774697. DOI: 10.3389/fnut.2024.1466509.


NIPAL1 as a prognostic biomarker associated with pancreatic adenocarcinoma progression and immune infiltration.

Zhu Y, Qi Z, Zu S, Yang F, Wang Y, Zhu L BMC Cancer. 2025; 25(1):165.

PMID: 39875873 PMC: 11776251. DOI: 10.1186/s12885-025-13567-5.


Normal tissue complication probability model for severe radiation-induced lymphopenia in patients with pancreatic cancer treated with concurrent chemoradiotherapy.

Koizumi F, Katoh N, Kanehira T, Kawamoto Y, Nakamura T, Kakisaka T Phys Imaging Radiat Oncol. 2025; 33():100690.

PMID: 39817285 PMC: 11733268. DOI: 10.1016/j.phro.2024.100690.


Pathological complete response following neoadjuvant chemotherapy with PD-1 inhibitor for locally advanced pancreatic cancer: case report.

Chen J, Wang D, Xiong F, Wu G, Liu W, Wang Q J Gastrointest Oncol. 2025; 15(6):2692-2705.

PMID: 39816022 PMC: 11732357. DOI: 10.21037/jgo-24-549.